Patents Assigned to City of Hope
  • Adeno-associated virus compositions for restoring F8 gene function and methods of use thereof
    Patent number: 11306329
    Abstract: Provided herein are adeno-associated virus (AAV) compositions that can restore F8 gene function in a cell without co-transducing or co-administering an exogenous nuclease or a nucleotide sequence that encodes an exogenous nuclease. Also provided are methods of using the AAV compositions to correct an F8 gene mutation and/or treat a disease or disorder associated with an F8 gene mutation. Packaging systems for making the adeno-associated virus compositions are also provided.
    Type: Grant
    Filed: February 19, 2019
    Date of Patent: April 19, 2022
    Assignees: CITY OF HOPE, HOMOLOGY MEDICINES, INC.
    Inventors: Saswati Chatterjee, Laura Jane Smith, Jeff Lynn Ellsworth, Hillard Rubin, Jason Boke Wright, James Anthony McSwiggen
  • 5-bromo-indirubins
    Patent number: 11306072
    Abstract: Disclosed herein inter alia are compositions and methods for treating cancer using 5-Br-indirubin derivatives.
    Type: Grant
    Filed: February 13, 2020
    Date of Patent: April 19, 2022
    Assignees: City of Hope, National and Kapodistrian University of Athens
    Inventors: Richard Jove, Sangkil Nam, David Horne, Jun Xie, Alexios Leandros Skaltsounis, Marina Kritsanida, Nicolas Gaboriaud-Kolar
  • Tumor-selective CTLA-4 antagonists
    Patent number: 11279752
    Abstract: Provided herein are recombinant masking proteins and recombinant ligand proteins useful in treating cancer, neurodegenerative disease, and cardiovascular disease. The recombinant masking proteins provided herein may, inter alia, be used as non-covalent masks of antagonists of, for example, cellular growth factors (e.g., TNF) or cell surface proteins (e.g., CTLA-4).
    Type: Grant
    Filed: September 3, 2019
    Date of Patent: March 22, 2022
    Assignees: CITY OF HOPE, THOMAS JEFFERSON UNIVERSITY
    Inventors: John C. Williams, Ulrich Rodeck, Kurt Jenkins
  • Chimeric immunoreceptor useful in treating human cancers
    Patent number: 11278594
    Abstract: The present invention relates to chimeric transmembrane immunoreceptors, named “zetakines,” comprised of an extracellular domain comprising a soluble receptor ligand linked to a support region capable of tethering the extracellular domain to a cell surface, a transmembrane region and an intracellular signalling domain. Zetakines, when expressed on the surface of T lymphocytes, direct T cell activity to those specific cells expressing a receptor for which the soluble receptor ligand is specific. Zetakine chimeric immunoreceptors represent a novel extension of antibody-based immunoreceptors for redirecting the antigen specificity of T cells, with application to treatment of a variety of cancers, particularly via the autocrin/paracrine cytokine systems utilized by human malignancy.
    Type: Grant
    Filed: December 20, 2019
    Date of Patent: March 22, 2022
    Assignee: City of Hope
    Inventor: Michael Jensen
  • COMBINATION THERAPY COMPRISING CANCER-TARGETED CAR-T CELLS AND A METHOD OF USING SAME FOR A TREATMENT FOR CANCER
    Publication number: 20220072043
    Abstract: Described are improved methods for treating solid tumors, such as malignant gliomas, with a dual approach utilizing a CAR-T immunotherapy and a viral oncolytic therapy.
    Type: Application
    Filed: September 9, 2021
    Publication date: March 10, 2022
    Applicants: Mustang Bio, Inc., Beckman Research Institute of the City of Hope
    Inventors: Knut Niss, Sadik H. Kassim, Christine E. Brown, Stephen J. Forman, Behnam Badie
  • Methods of quantifying N-(1-carboxyethyl)-2?-deoxy-guanosine (CEdG) and synthesis of oligonucleotides containing CEdG
    Patent number: 11266618
    Abstract: Methods of quantifying N2-carboxyethyl-2?-deoxyguanosine (CEdG) levels in biological samples and comparing those levels to known normal levels can diagnose a number of disorders, including diabetes and cancer. Methods can also determine whether therapies for disorders are effective by measuring CEdG levels before and after treatment. Measurement of CEdG levels occurs using liquid chromatography electrospray ionization tandem mass spectrometry.
    Type: Grant
    Filed: December 29, 2017
    Date of Patent: March 8, 2022
    Assignee: CITY OF HOPE
    Inventors: Samuel Rahbar, Timothy W. Synold, John Termini, Daniel Tamae, Gerald Wuenschell
  • Markers of breast cancer and methods for the use thereof
    Patent number: 11268152
    Abstract: In accordance with the present invention, the single gene SERPINA1 has been identified as a significant predictor of survival in ER+ and ER+/HER2+ breast cancer patients. For example, patients with ER+/FIER2+ breast cancer generally have a worse outcome compared to ER+/FIER2? and ER?/FIER2+ patients. Currently there is no known predictive marker for the treatment C outcome of ER+ and ER+/FIER2+ breast cancers, thus the ability of SERPINA1 to predict the survival of this intrinsic subtype of breast cancer patients is valuable.
    Type: Grant
    Filed: January 19, 2016
    Date of Patent: March 8, 2022
    Assignee: CITY OF HOPE
    Inventors: Shiuan Chen, Hei Jason Chan
  • Anti-cancer RNA aptamers
    Patent number: 11261449
    Abstract: Provided herein, inter alia, are compounds capable of binding HSP70 (e.g. mHSP70) on a cell and internalizing into said cell. The compositions provided herein may be useful for delivering therapeutic and diagnostic agents to a cell. Further provided are pharmaceutical compositions and methods of treatment using nucleic acid compounds provided herein.
    Type: Grant
    Filed: December 18, 2019
    Date of Patent: March 1, 2022
    Assignees: City of Hope, Apierna Ltd
    Inventors: John J. Rossi, Sorah Yoon, Nagy Habib
  • Methods and compositions for measuring beta cell death
    Patent number: 11261491
    Abstract: Provided herein are, inter alia, nucleic acids, methods, and kits for detecting unmethylated DNA in body fluid sample of a subject. The disclosure includes compositions, methods, and kits for detecting unmethylation at a CpG site in an insulin gene promoter of a subject.
    Type: Grant
    Filed: July 8, 2019
    Date of Patent: March 1, 2022
    Assignee: City of Hope
    Inventors: Kevin Ferreri, Mohamed I. Husseiny Elsayed
  • Meditopes and meditope-binding antibodies and uses thereof
    Patent number: 11246942
    Abstract: Antibodies and meditopes that bind to the antibodies are provided, as well as complexes, compositions and combinations containing the meditopes and antibodies, and methods of producing, using, testing, and screening the same, including therapeutic and diagnostic methods and uses.
    Type: Grant
    Filed: June 5, 2017
    Date of Patent: February 15, 2022
    Assignee: City of Hope
    Inventors: John C. Williams, David A. Horne, Yuelong Ma, Heng Wei Chang, Joshua Michael Donaldson, Cindy Zer, Krzysztof Bzymek, Kendra Nicole Avery, Jun Xie
  • BAFF-R ANTIBODIES AND USES THEREOF
    Publication number: 20220041743
    Abstract: Provided herein are BAFF-R antibodies as well as compositions and methods of making and using the same. The antibodies provided herein are, inter alia, useful for the treatment of cancer and autoimmune diseases.
    Type: Application
    Filed: August 16, 2021
    Publication date: February 10, 2022
    Applicants: CITY OF HOPE, BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Hong QIN, Larry W. KWAK, Jingxing LI, Kexin HUANG
  • Compositions and methods for the treatment of hypercholesterolemia
    Patent number: 11242531
    Abstract: Provided herein are, inter alia, compositions and methods for the treatment of hypercholesterolemia. The compositions include double-stranded and single-stranded RNAs capable of repressing IncRNA and concomitantly increasing LDLR activation. The compositions are useful for activating LDLR in liver cells.
    Type: Grant
    Filed: February 2, 2018
    Date of Patent: February 8, 2022
    Assignee: CITY OF HOPE
    Inventors: Kevin V. Morris, Roslyn Ray
  • DNA methylation diagnostic test for breast cancer
    Patent number: 11242568
    Abstract: The present subject matter provides, inter alia, a method of diagnosing invasive ductal cancer or detecting invasive ductal cancer risk in a subject who has ductal carcinoma in situ, a method of treating breast cancer in a subject detected to have invasive ductal cancer or determined to be at risk of invasive ductal cancer, compositions for detecting invasive presence or potential in ductal carcinoma in situ in a subject, and kits including reagents and composition for detecting invasive presence or potential in ductal carcinoma in situ in a subject.
    Type: Grant
    Filed: December 28, 2018
    Date of Patent: February 8, 2022
    Assignee: City of Hope
    Inventors: Maria A. Hahn, John H. Yim, Yuman Fong, Arthur X. Li, Xiwei Wu, Sun-Wing T. R. Tong
  • CONDITIONING REGIMENS AND METHODS FOR INDUCING MIXED CHIMERISM
    Publication number: 20220031716
    Abstract: Disclosed herein are conditioning regimens and methods for inducing MHC- or HLA-mismatched mixed chimerism by conditioning a recipient with radiation-free, low-doses of cyclophosphamide (CY), pentostatin (PT), and anti-thymocyte globulin (ATG) prior to transplantation of donor bone marrow cells. In certain embodiments, the donor bone marrow cells may be CD4+ T-depleted bone marrow cells. The conditioning regimens and methods may also include administering one or more populations of conditioning donor cells selected from donor CD4+ T-depleted spleen cells, donor CD8+ T cells, and donor G-CSF-mobilized peripheral blood mononuclear cells. The conditioning regimen is clinically acceptable and can be used for treating hereditary hematological diseases and autoimmune diseases, as well as for promoting organ transplantation immune tolerance.
    Type: Application
    Filed: August 11, 2021
    Publication date: February 3, 2022
    Applicant: CITY OF HOPE
    Inventor: Defu ZENG
  • RNA aptamers against transferrin receptor (TFR)
    Patent number: 11236341
    Abstract: Provided herein, inter alia, are nucleic acid compounds capable of binding transferrin receptor on a cell and internalizing into said cell. The compositions provided herein may be useful for delivering therapeutic and diagnostic agents to a cell. Further provided are pharmaceutical compositions and methods of treatment using nucleic acid compounds provided herein.
    Type: Grant
    Filed: October 15, 2015
    Date of Patent: February 1, 2022
    Assignees: City of Hope, Apterna Ltd
    Inventors: John J. Rossi, Sorah Yoon, Nagy Habib
  • Synthesis of ETP derivatives
    Patent number: 11230560
    Abstract: Provided herein, inter alia, is the synthesis of ETP derivatives. The synthetic methods described herein include converting a ring bridging trisulfide compound of formula to a ring bridging disulfide compound of formula Also provided herein are compositions comprising thereof.
    Type: Grant
    Filed: May 22, 2018
    Date of Patent: January 25, 2022
    Assignee: CITY OF HOPE
    Inventors: David Horne, Jun Xie
  • Chimeric antigen receptors containing a chlorotoxin domain
    Patent number: 11230577
    Abstract: Chimeric transmembrane immunoreceptors (CAR) which include an extracellular domain that includes chlorotoxin or a related toxin, or a variant of chlorotoxin or a related toxin, that binds to human glioma or other human tumor cells, a transmembrane region, a costimulatory domain and an intracellular signaling domain are described.
    Type: Grant
    Filed: October 13, 2016
    Date of Patent: January 25, 2022
    Assignee: City of Hope
    Inventors: Michael Barish, Christine E. Brown, Stephen J. Forman, Dongrui Wang
  • P38 map kinase inhibitors
    Patent number: 11225665
    Abstract: Provided herein, inter alia, are p38 mitogen-activated protein kinase inhibitors and methods of treating cancer using p38 mitogen-activated protein kinase inhibitors.
    Type: Grant
    Filed: June 15, 2020
    Date of Patent: January 18, 2022
    Assignee: CITY OF HOPE
    Inventors: John J. Rossi, Sorah Yoon
  • BAFF-R TARGETED CHIMERIC ANTIGEN RECEPTOR-MODIFIED T-CELLS AND USES THEREOF
    Publication number: 20220010023
    Abstract: Provided herein are T cells expressing a chimeric antigen receptor (CAR) targeted to B cell activating factor receptor (BAFF-R). The CAR targeted to BAFF-R (BAFF-R CAR) described herein includes a domain that binds BAFF-R. Methods of making and using the BAFF-R CAR are also provided.
    Type: Application
    Filed: September 3, 2021
    Publication date: January 13, 2022
    Applicants: CITY OF HOPE, BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Hong QIN, Larry W. KWAK
  • Bi-specific aptamer
    Patent number: 11219635
    Abstract: Provided are aptamers and aptamer compositions and particularly, although not exclusively, to a bi-specific aptamer capable of binding a tumor cell antigen and an immune cell surface protein.
    Type: Grant
    Filed: February 17, 2017
    Date of Patent: January 11, 2022
    Assignees: City of Hope, Apterna Limited
    Inventors: John J. Rossi, Sorah Yoon, Nagy Habib